Optimi Health Corp (OPTI) has signed a supply agreement with Filament Health, a clinical-stage natural psychedelic drug development company.

Filament has engaged Optimi to supply psilocybin mushrooms cultivated in Optimi’s recently inaugurated 20,000 square foot EU-GMP Princeton, British Columbia, facility to produce whole, dried mushroom fruiting bodies for potential drug development and analysis by Filament’s research team.

“Our supply agreement with Filament Health is an excellent fit for both parties,” stated Optimi CEO Bill Ciprick.

“Filament’s commitment to developing unique intellectual properties using natural psychedelic medicines and the advancement of natural psilocybin in the space as a whole is well-aligned with our values and goals for the future of psychedelics,” he added.

“We are pleased to partner with Optimi as we build out our own supply chain and explore external suppliers,” noted Filament Health CEO and Co-Founder Benjamin Lightburn.

“This is an important step for Filament, and we look forward to determining the compatibility of Optimi’s product with our industry-leading natural extraction technology,” he added.

The two companies believe that the agreement sends a strong message that safety and research are paramount to growing a safe and secure supply of natural psilocybin.

Optimi Health Corp. is a homegrown company producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.

Filament Health is a clinical-stage natural psychedelic drug development company.

Optimi Health Corp. (OPTI) opened trading at $0.35.